Last A$0.84 AUD
Change Today +0.04 / 5.00%
Volume 1.1M
As of 12:10 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

impedimed ltd (IPD) Snapshot

Open
A$0.83
Previous Close
A$0.80
Day High
A$0.86
Day Low
A$0.83
52 Week High
01/30/15 - A$1.00
52 Week Low
06/12/14 - A$0.17
Market Cap
246.3M
Average Volume 10 Days
677.5K
EPS TTM
A$-0.05
Shares Outstanding
293.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPEDIMED LTD (IPD)

Related News

No related news articles were found.

impedimed ltd (IPD) Related Businessweek News

No Related Businessweek News Found

impedimed ltd (IPD) Details

ImpediMed Limited develops, manufactures, and sells bioimpedance and bioimpedance spectroscopy devices, and consumables for clinicians and allied health professionals in Australia, Canada, Mexico, The United States, and internationally. The company operates through Medical, and Test & Measurement segments. The Medical segment offers non-invasive medical devices for the assessment and monitoring of secondary lymphoedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring, and sports medicine and fitness, as well as body composition and hydration. The Test & Measurement segment supplies power precision testing and measuring equipment. The company offers its products through distributors. ImpediMed Limited was founded in 1999 and is based in Pinkenba, Australia.

30 Employees
Last Reported Date: 08/27/14
Founded in 1999

impedimed ltd (IPD) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: A$571.1K
Chief Financial Officer
Total Annual Compensation: A$282.2K
Vice President of Global Commercialization
Total Annual Compensation: A$313.4K
Vice President of Product Development, Qualit...
Total Annual Compensation: A$267.7K
Vice President of Regulatory, Clinical Affair...
Total Annual Compensation: A$267.7K
Compensation as of Fiscal Year 2014.

impedimed ltd (IPD) Key Developments

ImpediMed Limited Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

ImpediMed Limited reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue of AUD 2,110,000 and net loss attributable to owners of the parent AUD 6,122,000 or AUD 0.03 per diluted share against revenue of AUD 1,645,000 and net loss attributable to owners of the parent AUD 3,586,000 or AUD 0.02 per diluted share for the same period a year ago. Net cash used in operating activities was AUD 4,143,000 against AUD 2,804,000 for the same period a year ago. Purchase of equipment was AUD 118,000 against AUD 30,000 for the same period a year ago.

ImpediMed Limited Announces Executive Changes

ImpediMed Limited announced the appointment of Ms. Leanne Ralph as Company Secretary effective immediately. Ms. Ralph has 15 years experience providing company Secretarial services to a range of publicly listed companies in Australia. Ms. Ralph replaces Mr. Stephen Denaro who has been Company Secretary since September 2009, and previously from March 2003 through April 2008.

ImpediMed Limited, Annual General Meeting, Oct 30, 2014

ImpediMed Limited, Annual General Meeting, Oct 30, 2014., at 14:00 E. Australia Standard Time. Location: Corrs Chambers Westgarth Level 42. Agenda: To consider the annual financial report of the company, together with the directors' report and auditor's report, for the year ended June 30, 2014; to consider remuneration report; to elect directors; to consider to issue shares; and to approve the employee incentive plan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPD:AU A$0.84 AUD +0.04

IPD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPD.
View Industry Companies
 

Industry Analysis

IPD

Industry Average

Valuation IPD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.1x
Price/Book 5.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPEDIMED LTD, please visit www.impedimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.